Latest Insider Transactions at Pharma Cyte Biotech, Inc. (PMCB)
This section provides a real-time view of insider transactions for Pharma Cyte Biotech, Inc. (PMCB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PharmaCyte Biotech, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PharmaCyte Biotech, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
Jonathan Schechter Director |
BUY
Open market or private purchase
|
Direct |
20,000
+9.41%
|
$0
$0.84 P/Share
|
|
Jan 07
2026
|
Joshua Silverman CEO and President |
BUY
Open market or private purchase
|
Direct |
40,000
+8.77%
|
$0
$0.83 P/Share
|
|
Jan 06
2026
|
Jonathan Schechter Director |
BUY
Open market or private purchase
|
Direct |
20,000
+10.39%
|
$0
$0.79 P/Share
|
|
Jan 06
2026
|
Joshua Silverman CEO and President |
BUY
Open market or private purchase
|
Direct |
30,000
+7.38%
|
$0
$0.79 P/Share
|
|
Jan 05
2026
|
Jonathan Schechter Director |
BUY
Open market or private purchase
|
Direct |
20,000
+11.59%
|
$0
$0.78 P/Share
|
|
Jan 05
2026
|
Joshua Silverman CEO and President |
BUY
Open market or private purchase
|
Direct |
30,000
+7.97%
|
$0
$0.78 P/Share
|
|
Dec 12
2025
|
Michael M Abecassis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
16,875
-43.08%
|
$16,875
$1.02 P/Share
|
|
Dec 12
2025
|
Michael M Abecassis Director |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+48.91%
|
-
|
|
Dec 12
2025
|
Jonathan Schechter Director |
SELL
Payment of exercise price or tax liability
|
Direct |
67,500
-33.75%
|
$67,500
$1.02 P/Share
|
|
Dec 12
2025
|
Jonathan Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+42.86%
|
-
|
|
Dec 12
2025
|
Joshua Silverman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
258,750
-45.0%
|
$258,750
$1.02 P/Share
|
|
Dec 12
2025
|
Joshua Silverman CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
575,000
+50.0%
|
-
|
|
Dec 12
2025
|
Wayne Remell Walker Director |
SELL
Payment of exercise price or tax liability
|
Direct |
16,875
-45.0%
|
$16,875
$1.02 P/Share
|
|
Dec 12
2025
|
Wayne Remell Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Dec 12
2025
|
Robert Weinstein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
33,750
-45.0%
|
$33,750
$1.02 P/Share
|
|
Dec 12
2025
|
Robert Weinstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|